Nature Reviews Cancer contents April 2012 Volume 12 Number 4 pp 227-313

Advertisement
Monitor Cell Invasion and Migration in Real-Time Take a step forward in cancer research with the xCELLigence System. The CIM-plate 16 from Roche uses electronic sensing to directly study cell migration and invasion without exogenous labels.  For life science research only, not for use in diagnostic procedures.  Visit: http://www.xCELLigence.roche.com
TABLE OF CONTENTS
April 2012 Volume 12 Number 4		Advertisement
Impact Factor 37.178 *	In this issue Research Highlights Foreword Focus on: Tumour immunology & immunotherapy Also this month  Featured article: Combining immunotherapy and targeted therapies in cancer treatment Matthew Vanneman & Glenn Dranoff	Accurately measure subcutaneous tumors The TumorImager(TM) rapidly scans subcutaneous tumors (~1 sec) without requiring anesthesia, providing highly sensitive, reproducible measurements of drug response in your preclinical oncology studies saving time and money. TumorManagerTM can handle all aspects of your animal studies from protocol design to analysis. For a free web demo: http://www.biopticon.com/ tumorImager.php
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
The New Standard in FFPE Analysis Leading cancer researchers worldwide are utilizing NanoString’s nCounter® Analysis System to explore the frontiers of cancer biology. The system enables very precise, digital quantification of up to 800 nucleic acid targets per reaction and is compatible with FFPE samples up to 20 years old. Click to learn more.
RESEARCH HIGHLIGHTS Top Tumour immunogenicity: Editorial selection demystified p227 | doi:10.1038/nrc3251 Two studies uncover details of the antigens and immune responses that are involved in the immunoediting of tumours. PDF Tumour immunology: Suppressing tumorigenic inflammation p228 | doi:10.1038/nrc3252 A paper uncovers a RAS–RAL GEF signalling pathway that activates AKT and RAL GTPases to promote survival and motility, and which is inhibited by the expression of the anti-inflammatory mediator TIPE2. PDF Metastasis: Multitasking hyaluronic acid p228 | doi:10.1038/nrc3254 Inhibition of the hyaluronic acid scavenger receptor stabilin 2 blocks metastasis by preventing the attachment of tumour cells to lung endothelial cells. PDF Metabolism: Unmasking an oncometabolite p229 | doi:10.1038/nrc3248 Mutant IDH genes that produce 2-hydroxyglutarate can influence cell transformation through effects on DNA and histone methylation and hypoxia inducible factors. PDF Leukaemia: Adding e for survival p230 | doi:10.1038/nrc3249 Stromal cells take up and convert cystine into cysteine, which is used by chronic lymphocytic leukaemia cells to increase glutathione levels and to protect them against increased levels of reactive oxygen species and chemotherapeutic drugs. PDF Tumour immunology: Dendritic cell switch p230 | doi:10.1038/nrc3253 Jose Conejo-Garcia and colleagues show that dendritic cells from mice in the early stages of ovarian tumorigenesis are immunocompetent and hinder tumour progression, but that they become immunosuppressive in advanced tumours and promote tumour progression. PDF Immunotherapy: Combinations that work p231 | doi:10.1038/nrc3250 Two papers report preclinical data in support of combining targeted cancer therapies with immune stimulation mediated by CD137 activation. PDF Cancer JOBS of the week Postdoctoral Position: Gene Expression Regulation in Breast Cancer / Stem Cell Biology UC College of Medicine Associate professor in cancer biology or immunology Universsity of Southern Denmark, The Department of Cancer and Inflammation, Institute of Molecular Medicine, Cancer Research Scientist Stony Brook University Postdoc in cancer stem cell biology Institute of Neuropathology, Justus Liebig University Giessen, Germany More Science jobs from Cancer EVENT Nobel Conference on Breast Cancer 14.-17.06.12 Stockholm, Sweden More science events from
FOREWORD		Top
Tumour immunotherapy — leukocytes take up the fight Gemma K. Alderton & Yvonne Bordon p235 | doi:10.1038/nrc3255 An introduction to the contents of the joint Focus on Tumour immunology & immunotherapy from Nature Reviews Cancer and Nature Reviews Immunology. Abstract | Full Text | PDF
Advertisement
Rapid somatic mutation analysis powered by Assays by Sequenom • Rapidly validate or profile somatic mutations in tumor samples • Select from our research use OncoCarta™ family of 600 assays • Or send us your list by gene, pathway, or tissue • Let us design the assays and run your samples • No instrumentation or system required
Focus on: Tumour immunology & immunotherapy REVIEWS Top Combining immunotherapy and targeted therapies in cancer treatment Matthew Vanneman & Glenn Dranoff p237 | doi:10.1038/nrc3237 Targeted therapies can be used to successfully treat cancer patients, but what are their mechanisms of action? This Review discusses how targeted therapies modulate the immune system and how they can be rationally combined with immunotherapies. Abstract | Full Text | PDF The blockade of immune checkpoints in cancer immunotherapy Drew M. Pardoll p252 | doi:10.1038/nrc3239 Immune checkpoints refer to the plethora of inhibitory pathways that are crucial to maintaining self-tolerance. Tumour cells induce immune checkpoints to evade immunosurveillance. This Review discusses the progress in targeting immune checkpoints, the considerations for combinatorial therapy and the potential for additional immune-checkpoint targets. Abstract | Full Text | PDF Cancer immunotherapy via dendritic cells Karolina Palucka & Jacques Banchereau p265 | doi:10.1038/nrc3258 Dendritic cells have far-reaching and important effects on the activation of the immune response; thus, they are used to vaccinate patients with cancer to induce long-term anti-tumour immunity. This Review discusses what we know — and need to know — about dendritic cells to improve how they are used therapeutically. Abstract | Full Text | PDF Antibody therapy of cancer Andrew M. Scott, Jedd D. Wolchok & Lloyd J. Old p278 | doi:10.1038/nrc3236 The development of therapeutic antibodies requires a substantial understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies required to develop antibody therapies for cancer patients. Abstract | Full Text | PDF PERSPECTIVES Top OPINION Unmasking the immune recognition of prostate cancer with CTLA4 blockade Serena S. Kwek, Edward Cha & Lawrence Fong p289 | doi:10.1038/nrc3223 Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) represents a crucial immune checkpoint, the blockade of which can potentiate anti-tumour immunity. This treatment in patients with advance prostate cancer may provide insights into the targets that the immune system recognizes to drive tumour regression. Abstract | Full Text | PDF OPINION The immune contexture in human tumours: impact on clinical outcome Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman & Jérôme Galon p298 | doi:10.1038/nrc3245 The infiltration of various types of immune cells is common to most tumour microenvironments. As discussed in this Opinion article, the pattern of immune cell infiltration varies between cancer type and individual tumours of the same type, and this pattern can be used to indicate prognosis and response to therapy. Abstract | Full Text | PDF VIEWPOINT The determinants of tumour immunogenicity Thomas Blankenstein, Pierre G. Coulie, Eli Gilboa & Elizabeth M. Jaffee p307 | doi:10.1038/nrc3246 Four leading tumour immunologists provide their opinions on the determinants of immunogenicity and how we might therapeutically improve tumour immunogenicity in the future. Abstract | Full Text | PDF
Advertisement
Nature Outlook: Lenses on Biology In this special edition of Nature Outlook, five top scientists explain how research in their specialties - cancer, climate change, stem cells, oceanography and synthetic biology - has changed our lives. Access the Outlook free online for six months. Produced in partnership with Nature Education.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.